{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:27:12Z","timestamp":1791390432739,"version":"4.3.3"},"reference-count":50,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T00:00:00Z","timestamp":1515628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2016JJ3083"],"award-info":[{"award-number":["2016JJ3083"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Nasal\u2010type extranodal natural killer <jats:styled-content style=\"fixed-case\">NK<\/jats:styled-content>\/T\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">ENKTCL<\/jats:styled-content>) i<jats:bold>s<\/jats:bold> a distinct type of non\u2010Hodgkin lymphoma with poor prognosis. This research aimed to evaluate the efficacy and safety of the <jats:styled-content style=\"fixed-case\">GELOXD<\/jats:styled-content> or P\u2010<jats:styled-content style=\"fixed-case\">GEMOXD<\/jats:styled-content> regimens in patients with <jats:styled-content style=\"fixed-case\">ENKTCL<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Newly diagnosed <jats:styled-content style=\"fixed-case\">ENKTCL<\/jats:styled-content> patients treated with either the\u00a0<jats:styled-content style=\"fixed-case\">GELOXD<\/jats:styled-content> or the P\u2010<jats:styled-content style=\"fixed-case\">GEMOXD<\/jats:styled-content> regimen were identified from three cancer centers between January 2010 and December 2016. Kaplan\u2010Meier and Cox regression analyses were used to calculate overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) and progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) and to investigate prognostic factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and eighty\u2010four cases were identified from three cancer centers. After 1\u20105 treatment cycles of <jats:styled-content style=\"fixed-case\">GELOXD<\/jats:styled-content> or P\u2010<jats:styled-content style=\"fixed-case\">GEMOXD<\/jats:styled-content> chemotherapy, 155 (84%) patients showed a complete response (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>). The 3\u2010year <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> (73.0% vs 38.2%, <jats:italic>P\u00a0=<\/jats:italic>\u00a0.001) and <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> (72.8% vs 32.4%, <jats:italic>P\u00a0=<\/jats:italic>\u00a0.000) rates were significantly higher in early\u2010stage patients compared with advanced\u2010stage patients. A multivariate analysis revealed that patient <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> status was a significant independent factor in disease prognosis. Grade 3\/4 leukopenia occurred in 43 (23.4%) patients. Major non\u2010hematological toxicities included nausea (n\u00a0=\u00a0117, 63.6%) and vomiting (n\u00a0=\u00a066, 35.9%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The <jats:styled-content style=\"fixed-case\">GELOXD<\/jats:styled-content> and P\u2010<jats:styled-content style=\"fixed-case\">GEMOXD<\/jats:styled-content> chemotherapy regimens are well tolerated and provide favorable survival outcomes in patients with <jats:styled-content style=\"fixed-case\">ENKTCL<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13004","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T14:22:38Z","timestamp":1512051758000},"page":"247-256","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and tolerance of <scp>GELOXD<\/scp>\/P\u2010<scp>GEMOXD<\/scp> in newly diagnosed nasal\u2010type extranodal <scp>NK<\/scp>\/T\u2010cell lymphoma: A multicenter retrospective study"],"prefix":"10.1111","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-6512","authenticated-orcid":false,"given":"Ji\u2010Wei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Hematology Hunan Cancer Hospital  Changsha Hunan China"},{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya\u2010Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Hematology Hunan Cancer Hospital  Changsha Hunan China"},{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei\u2010Zuo","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Oncology Xiangya Hospital Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian\u2010Ling","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center of the Second Xiangya Hospital Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8431-8117","authenticated-orcid":false,"given":"Jin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Hematology Hunan Cancer Hospital  Changsha Hunan China"},{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun\u2010Lun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Hematology Hunan Cancer Hospital  Changsha Hunan China"},{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi\u2010Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Hematology Hunan Cancer Hospital  Changsha Hunan China"},{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Hematology Hunan Cancer Hospital  Changsha Hunan China"},{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"OuYang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Hematology Hunan Cancer Hospital  Changsha Hunan China"},{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong\u2010Yi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Hematology Hunan Cancer Hospital  Changsha Hunan China"},{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u2010Jun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Hematology Hunan Cancer Hospital  Changsha Hunan China"},{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun\u2010Qiao","family":"He","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Hematology Hunan Cancer Hospital  Changsha Hunan China"},{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Hematology Hunan Cancer Hospital  Changsha Hunan China"},{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping\u2010Yong","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Hematology Hunan Cancer Hospital  Changsha Hunan China"},{"name":"The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-453233"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP7YLTQPUSDQ5C"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1108415"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26167"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.10.040"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.08.040"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.02.039"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1174-y"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011144911781"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1182\/blood.V89.8.2966","article-title":"CD3\u2212\u00a0CD56+ non\u2010Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance","volume":"89","author":"Dr\u00e9nou B","year":"1997","journal-title":"Blood"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2017.1254194"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05694.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8643"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27752"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2395-y"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2002-06-1901","article-title":"Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration","volume":"101","author":"Nowak\u2010G\u00f6ttl U","year":"2002","journal-title":"Blood"},{"key":"e_1_2_7_18_1","first-page":"285","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Chan JKC","year":"2008"},{"key":"e_1_2_7_19_1","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00533-1"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.1384"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0637-1"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6287"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431460"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26629"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-44"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2137-6"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2014.15.15.6275"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2014.368"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11319"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0153"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.12.003"},{"key":"e_1_2_7_35_1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-014-2228-4","article-title":"Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L\u2010asparaginase as a first\u2010line therapy improves outcomes in stage III\/IV NK\/T cell\u2010lymphoma, nasal type (NTCL)","volume":"94","author":"Kim M","year":"2014","journal-title":"Ann Hematol"},{"key":"e_1_2_7_36_1","first-page":"17","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T\u2010cell lymphoma failing L\u2010asparaginase","volume":"129","author":"Kwong YLCTS","year":"2017","journal-title":"Blood"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.003"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.65"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn147"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23422"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm183"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2244-4"},{"key":"e_1_2_7_43_1","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"19","author":"Hasenclever D","year":"1998","journal-title":"N Engl J Med"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064158"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)93284-9"},{"key":"e_1_2_7_47_1","first-page":"3992","article-title":"Association of \u03b22\u2010microglobulin with the prognosis of non\u2010Hodgkin's lymphoma: a meta analysis","volume":"8","author":"Wang XL","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"e_1_2_7_48_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5045\/br.2014.49.3.148","article-title":"Serum beta\u20102 microglobulin in malignant lymphomas: an old but powerful prognostic factor","volume":"49","author":"Yoon C","year":"2014","journal-title":"Blood Res"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1434-1"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-307454"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2017.1344100"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T11:32:15Z","timestamp":1695727935000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,11]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/ejh.13004"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13004","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,11]]}}}